Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood sample study explores new target for inflammatory arthritis

NCT ID NCT03322618

Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at blood samples from 24 people with axial spondyloarthritis (a type of inflammatory arthritis) and 12 healthy volunteers to understand how a receptor called KIR3DL2 contributes to inflammation. Researchers also tested whether a drug called IPH4102 could reduce inflammation in the lab. No treatments were given to participants, so there was no direct benefit from taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Dec 2017

Finished

Sep 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent of the patient signed before any procedure planned to the protocol * SPA axial according to the criteria of the ASAS (international Assessment of SpondyloArthritis Society) * Known Status HLA B27 * Disease activates with a score of BASDAI = 4/10. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Score) is a composite indication(index), validated, used in the therapeutic essays and in current practice for the evaluation of the activity of the SPA. * Naive Patients of thorough treatment * Patients of 18 and more years old Exclusion Criteria: * Minors * Pregnant or breast-feeding Women * Adults under guardianship * People staying in a sanitary or social establishment * People in emergency situation * Not profitable People of a national insurance scheme * Private persons of freedom * Treatment by corticoids during the last 30 days before the inclusion * Treatment by anti-TNF or quite different biomedicine * Treatment by sulfasalazine * Reached concomitant by another active chronic inflammatory disease * Infection chronicles by VHB, VHC or HIV * Patients included in another study of clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis (AS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankylosing spondylitis (AS) Axial spondyloarthritis (axspa)

Contacts and locations

Locations

  • Assistance Publique Hopitaux de Marseille

    Marseille, 13354, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.